Frontlight ResearchEarly access
Not yet recruitingPhase 3
Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)
Key facts
- Who runs it
- Dr. Falk Pharma GmbH
- Where
- Austria, Belgium, Denmark, France, Germany, Hungary, Netherlands, Norway, Poland, and Sweden22 sites in 10 countriesChoose a country to see its sites
- Trial code
- NCT06886360
- EU 2024-514292-18-00
- ISRCTN58756615
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 120 people, planned
- Started
- Mar 2025
- Expected to end
- Sept 2027
- Type of study
- Interventional
- Treatments tested
- norucholic acid
- Record updated
- 20 March 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Signed informed consent
- Males or females ≥ 18 years
- Patient has previously been diagnosed with PSC, has participated in the previous NUC 5/PSC trial and has completed the DBE phase with Visit 22, or has prematurely terminated the DBE phase before this trial has been started, or has prematurely terminated the DBE phase after this trial has been started, under the condition that the premature termination was due to lack of efficacy*. (*Lack of efficacy as defined in the NUC-5/PSC trial.)
Who cannot take part
- Patients who discontinued study participation in NUC-5/PSC due to an AE possibly caused by the study drug
- History of liver transplantation or patient listed for transplantation
- History or presence of chronic alcoholic consumption (daily consumption > 30 g in men, > 20 g in women)
- Liver Cirrhosis or any cirrhosis-related symptoms which in the opinion of the investigator may affect the patient's safety
This trial has no sites in United States.
It has sites in 10 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Open-label, multi-center, phase III trial. Oral treatment with 1500 mg norucholic acid in Primary Sclerosing cholangitis
The group in the trial
- norucholic acid 1500 mg/dayTreatment being tested
3 film-coated tablets once daily for 72 weeks containing in total norUrsodeoxycholic acid 1500 mg
Treatment: norucholic acid
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An Open-label Study of Patients with Primary Sclerosing Cholangitis (PSC) Treated with Norucholic Acid Tablets
- Record updated
- 20 March 2025